Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C19H21FN2O4.C6H14N4O2 |
| Molecular Weight | 534.5804 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
N[C@@H](CCCNC(N)=N)C(O)=O.C[C@H]1CCC2=C3N1C=C(C(O)=O)C(=O)C3=CC(F)=C2N4CCC(O)CC4
InChI
InChIKey=WIFOPRFVQIVWTB-YBVIJTQESA-N
InChI=1S/C19H21FN2O4.C6H14N4O2/c1-10-2-3-12-16-13(18(24)14(19(25)26)9-22(10)16)8-15(20)17(12)21-6-4-11(23)5-7-21;7-4(5(11)12)2-1-3-10-6(8)9/h8-11,23H,2-7H2,1H3,(H,25,26);4H,1-3,7H2,(H,11,12)(H4,8,9,10)/t10-;4-/m00/s1
| Molecular Formula | C6H14N4O2 |
| Molecular Weight | 174.201 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
| Molecular Formula | C19H21FN2O4 |
| Molecular Weight | 360.3794 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 1 / 1 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Levonadifloxacin is the S-(-) isomer of the benzoquinolizine fluoroquinolone nadifloxacin and is two- to four-fold more active than the racemic mixture. Levonadifloxacin is a potent antibacterial agent against Gram-positive bacteria especially against methicillin resistance Staphylococcus aureus. It also possesses potent bactericidal activity against other resistant variants like quinolone-resistant Staphylococcus aureus, vancomycin and glycopeptide intermediate Staphylococcus aureus and vancomycin resistant Staphylococcus aureus. Intravenous dosage form developed to treat complicated skin and skin structure infections and has recently completed Phase III studies in India and Phase I studies in USA.
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey Medical Center. | 2003 Nov |
|
| Antianaerobic activity of a novel fluoroquinolone, WCK 771, compared to those of nine other agents. | 2004 Aug |
|
| Antistaphylococcal activity of WCK 771, a tricyclic fluoroquinolone, in animal infection models. | 2004 Dec |
|
| In vitro activity of the new quinolone WCK 771 against staphylococci. | 2004 Sep |
|
| Activity of the new quinolones WCK 771, WCK 1152 and WCK 1153 against clinical isolates of Streptococcus pneumoniae and Streptococcus pyogenes. | 2005 Dec |
|
| Activity of the new quinolone WCK 771 against pneumococci. | 2005 Jan |
|
| Recently approved and investigational antibiotics for treatment of severe infections caused by Gram-positive bacteria. | 2005 Oct |
|
| Validated chiral high-performance liquid chromatography method for a novel anti-methicillin-resistant Staphylococcus aureus fluoroquinolone WCK 771. | 2006 Mar 3 |
|
| The anti-methicillin-resistant Staphylococcus aureus quinolone WCK 771 has potent activity against sequentially selected mutants, has a narrow mutant selection window against quinolone-resistant Staphylococcus aureus, and preferentially targets DNA gyrase. | 2006 Nov |
|
| Nadifloxacin: a quinolone for topical treatment of skin infections and potential for systemic use of its active isomer, WCK 771. | 2006 Oct |
|
| Simple liquid chromatography-tandem mass spectrometry method for determination of novel anti-methicillin-resistant Staphylococcus aureus fluoroquinolone WCK 771 in human serum. | 2007 Feb 1 |
|
| In vitro activity of the quinolone WCK 771 against recent U.S. hospital and community-acquired Staphylococcus aureus pathogens with various resistance types. | 2009 Feb |
|
| Intrapulmonary Pharmacokinetics of Levonadifloxacin following Oral Administration of Alalevonadifloxacin to Healthy Adult Subjects. | 2018 Mar |
|
| In Vitro Activities of the Benzoquinolizine Fluoroquinolone Levonadifloxacin (WCK 771) and Other Antimicrobial Agents against Mycoplasmas and Ureaplasmas in Humans, Including Isolates with Defined Resistance Mechanisms. | 2018 Nov |
|
| Electrocardiographic Effects of a Supratherapeutic Dose of WCK 2349, a Benzoquinolizine Fluoroquinolone. | 2019 Jan |
|
| Identification of metabolites of novel Anti-MRSA fluoroquinolone WCK 771 in mouse, rat, rabbit, dog, monkey and human urine using liquid chromatography tandem mass spectrometry. | 2019 Jul |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 18:20:29 GMT 2023
by
admin
on
Sat Dec 16 18:20:29 GMT 2023
|
| Record UNII |
U2RV55F5O0
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
U2RV55F5O0
Created by
admin on Sat Dec 16 18:20:30 GMT 2023 , Edited by admin on Sat Dec 16 18:20:30 GMT 2023
|
PRIMARY | |||
|
306748-89-0
Created by
admin on Sat Dec 16 18:20:30 GMT 2023 , Edited by admin on Sat Dec 16 18:20:30 GMT 2023
|
PRIMARY | |||
|
9850037
Created by
admin on Sat Dec 16 18:20:30 GMT 2023 , Edited by admin on Sat Dec 16 18:20:30 GMT 2023
|
PRIMARY | |||
|
DTXSID60184714
Created by
admin on Sat Dec 16 18:20:30 GMT 2023 , Edited by admin on Sat Dec 16 18:20:30 GMT 2023
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SOLVATE->ANHYDROUS | |||
|
|
PARENT -> SALT/SOLVATE | |||
|
|
PARENT -> SALT/SOLVATE |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |